Microstructure Technology - 17/07/2020 An electronic nose for many applications Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Press release - 09/12/2021 New research project in mathematical oncology A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
Press release - 30/03/2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
Press release - 21/09/2022 ERC funding: How to deliver gene therapies to a specific target site? With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
Press release - 01/02/2021 Targeting a rapid market breakthrough for new vaccine production method In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
The Baden-Württemberg healthcare industry The pharmaceutical industry https://www.gesundheitsindustrie-bw.de/en/location/pharma
Press release - 06/07/2021 High-throughput metabolic profiling of single cells Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-throughput-metabolic-profiling-single-cells
Press release - 24/11/2022 Green chemistry: BAM investigates pharmaceutical production without solvents and CO2 emissions The Bundesanstalt für Materialforschung und -prüfung (BAM) is developing a more sustainable process to produce active pharmaceutical ingredients in a major EU project: The pilot project is intended to demonstrate the advantages of mechanochemistry for more environmentally friendly and CO2-neutral pharmaceutical production.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gruene-chemie-bam-erforscht-arzneimittelproduktion-ohne-loesungsmittel-und-co2-ausstoss
Biotech in outer space - 06/07/2022 yuri, a space start-up: weightlessness for commercial research Growing cells without the effect of gravity could revolutionise drug development. A start-up called yuri on Lake Constance enables made-to-measure experiments on the ISS for stem cells, artificial organs, surfaces and materials. On board the next mission are some mini-cell labs from Berlin's Charité and Goethe University Frankfurt.https://www.gesundheitsindustrie-bw.de/en/article/news/yuri-space-start-weightlessness-commercial-research
Press release - 18/07/2023 National Research Center for cutting-edge AI research in Tübingen celebrates inception On Tuesday, July 18, 2023, the Tübingen AI Center held a symposium to celebrate its permanent establishment as a national AI center. Since July 1, 2022, it has received 20 million euros a year in funding from the federal government and the state. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nationales-forschungszentrum-fuer-ki-spitzenforschung-tuebingen-feiert-seine-gruendung
Dossier - 10/11/2014 Cell and gene therapies from bench to bedside https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Press release - 01/03/2022 CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
Press release - 01/04/2022 FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
Press release - 31/01/2023 ERC Consolidator Grants for Two Researchers from KIT In the 2022 allocation round for the award of the prestigious Consolidator Grants of the European Research Council, researchers of Karlsruhe Institute of Technology (KIT) have been successful. For their projects in the fields of photovoltaics and medical sensor technology, physicist Ulrich W. Paetzold and chemist Frank Biedermann will receive approximately two million euros over the next five years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-fuer-zwei-forscher-des-kit
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Dossier - 20/12/2012 Medical technology serving healthcare Modern healthcare would be impossible without medical technology. The achievements in medical technology are indispensable for our health and quality of life. The range of medical technology available covers surgical instruments and implants to diagnostic methods and medical devices.https://www.gesundheitsindustrie-bw.de/en/article/dossier/medical-technology-serving-healthcare
Press release - 12/04/2022 Technology transfer award for PCR rapid test device for infection diagnostics Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-transfer-award-pcr-rapid-test-device-infection-diagnostics
Dossier - 13/05/2013 The human proteome the next major goal https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
Press release - 23/11/2021 Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
Press release - 01/03/2023 Pseudomonas aeruginosa Bacteria produce a molecule that paralyzes immune system cells Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pseudomonas-aeruginosa-bakterien-stellen-ein-molekuel-her-das-zellen-des-immunsystems-laehmt
Article - 28/03/2019 Supporting the human use of artificial intelligence Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible. https://www.gesundheitsindustrie-bw.de/en/article/news/supporting-the-human-use-of-artificial-intelligence
Press release - 05/03/2024 New Center for Synthetic Genomics Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU). https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics
Press release - 11/01/2023 Newly discovered surface structures may affect immune function Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function